TRANSACTIONS - CEC CAPITAL

Cancel

Date：2021-04

CEC Capital Served as Financial Advisor
Cancel

Date：2021-04
/index.php?a=shows&catid=34&id=561
Arrail Group (“Arrail” or the “Company), a leading dental service provider in China, announced that it has closed its Series E financing, with a transaction value of nearly $200M. The transaction was led by Temasek, with participation from OrbiMed, Ward Ferry, Hina Group, Industrial Bank and Mirae Asset. CEC Capital Group was the exclusive financial advisor on this transaction, and is proud to have advised Arrail since its Series A round of financing.
Cancel

Date：2021-04
/index.php?a=shows&catid=34&id=818
The innovative artificial joint company b-ONE successfully closed a B-round financing of several hundred of million RMB, marking it the the largest RMB financing in the domestic orthopedic joint sector in recent years. The funding was led by Huatai Zijin
Cancel

Date：2021-04
/index.php?a=shows&catid=34&id=819
On April 12, SUNING LSY announced the successful closing of a significant Series A financing with investment from CPE and ADV Partners. CEC Capital Group served as the exclusive financial advisor in this transaction for SUNING LSY.
Cancel

Date：2021-03
/index.php?a=shows&catid=34&id=560
PALO ALTO, CA, March 30, 2021 -- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints today announced the closing of a $73 million Series B1/2 financing. The round was led by Oceanpine Capital with participation from additional new investors including Octagon Capital and Sphera Funds Management, and existing investors, including Northern Light Venture Capital and Vivo Capital. In addition, the company received a strategic capital investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program? (LLS TAP), directed toward advancing the company’s work to treat blood cancers. CEC Capital Group was the exclusive financial advisor on this transaction.
Cancel

Date：2021-03
/index.php?a=shows&catid=34&id=821
HISTO, the first independent third-party pathology diagnostic center in China, recently announced the closing of its B round financing, raising over RMB 100 million. The round was led by Haier Medical with participation from Flyfot Ventures and other well
Cancel

Date：2021-03
/index.php?a=shows&catid=34&id=822
Shanghai Cell Therapy Group, a leading player in the cell therapy industry in China, has announced the successful closing of its Series D1 financing, raising nearly RMB 500 million. The round was jointly invested by Jiuzhou Venture, Sun Rock Capital, and
Cancel

Date：2021-03
/index.php?a=shows&catid=34&id=823
Thousand Oaks, a rapidly growing Contract Development and Manufacturing Organization (CDMO) and cell culture biotechnology company, announced today that it has raised over RMB 400 million in its Series C Financing in March 2021. This round of financing wa
Cancel

Date：2021-03
/index.php?a=shows&catid=34&id=824
Arctic Vision, a clinical-stage biotech company focused on innovative ophthalmology therapies, announced today that it has successfully raised over $100 million in B round financing. The financing was led by Loyal Valley Capital, with participation from T